News Image

Why the quality investor may take a look at NYSE:NVO.

By Mill Chart

Last update: Feb 26, 2024

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is suited for quality investing. Investors should of course do their own research, but we spotted NOVO-NORDISK A/S-SPONS ADR showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

What matters for quality investors.

  • NOVO-NORDISK A/S-SPONS ADR has achieved substantial revenue growth over the past 5 years, with a 15.74% increase. This signifies the company's ability to successfully capture market opportunities and generate sustained revenue growth.
  • NOVO-NORDISK A/S-SPONS ADR demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 152.0% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
  • NOVO-NORDISK A/S-SPONS ADR maintains a healthy Debt/Free Cash Flow Ratio of 0.39, indicating a strong financial position and prudent debt management. This ratio suggests the company has sufficient free cash flow to cover its debt obligations and highlights its ability to generate cash from operations.
  • NOVO-NORDISK A/S-SPONS ADR demonstrates consistent Profit Quality over the past 5 years, with a strong 92.21%. This indicates the company's ability to generate sustainable and reliable profits, showcasing its long-term profitability and financial stability.
  • NOVO-NORDISK A/S-SPONS ADR has experienced impressive EBIT growth over the past 5 years, with 17.25% increase. This reflects the company's effective operational performance and highlights its potential for long-term financial success.
  • With EBIT 5-year growth outpacing its Revenue 5-year growth, NOVO-NORDISK A/S-SPONS ADR showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

What else is there to say on the fundamentals of NYSE:NVO?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Taking everything into account, NVO scores 7 out of 10 in our fundamental rating. NVO was compared to 202 industry peers in the Pharmaceuticals industry. NVO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NVO is not priced too expensively while it is growing strongly. Keep and eye on this one! NVO also has an excellent dividend rating. With these ratings, NVO could be worth investigating further for dividend and growth and quality investing!.

Check the latest full fundamental report of NVO for a complete fundamental analysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.


This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.



NYSE:NVO (4/24/2024, 7:20:06 PM)

After market: 125 -1.16 (-0.92%)


-2.48 (-1.93%)

NVO News

News Image10 hours ago - InvestorPlace3 Biotech Stocks With Skyrocketing Potential: April 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

News Image15 hours ago - The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

News Image15 hours ago - InvestorPlace3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

News Image16 hours ago - The Motley FoolMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

News Image2 days ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Image2 days ago - InvestorPlace3 Stocks With the Potential to Surpass Analyst Expectations for 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

News Image2 days ago - Yahoo FinanceWhy Novo Nordisk Topped the Market Today

It's not only spending its capital on developing new drugs.

News Image2 days ago - The Motley FoolWhy Novo Nordisk Topped the Market Today

It's not only spending its capital on developing new drugs.

News Image3 days ago - BloombergTikTok’s Crackdown on Ozempic Influencers Threatens Weight-Loss Drug Hype Machine

Creators say the rules are unfair and harmful to their businesses

News Image4 days ago - The Motley Fool2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

These stocks probably won't be getting much cheaper.

News Image5 days ago - The Motley Fool3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

News Image5 days ago - Yahoo Finance3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

NVO Links
Follow us for more